Fidani L, Rooke K, Chartier-Harlin M C, Hughes D, Tanzi R, Mullan M, Roques P, Rossor M, Hardy J, Goate A
Department of Biochemistry, St Mary's Hospital Medical School, London, UK.
Hum Mol Genet. 1992 Jun;1(3):165-8. doi: 10.1093/hmg/1.3.165.
Following the identification of mutations in the beta-amyloid precursor protein (APP) gene in familial, early onset Alzheimer's disease (AD), we have developed a screening protocol using single strand conformation analysis (SSCA) to screen exon 17 for the known mutations within APP. In addition, we used this protocol to screen the other seventeen exons of APP and a three hundred and thirty base pair regulatory region of the promoter for new mutations in 9 families with early onset AD. Exons 16 and 17, which encode the deposited beta-amyloid peptide, were screened in a further 10 families. Our screening procedure identifies all the reported mutations within APP. While we have identified a further family with APP717 Val-->Ile, we did not find any previously undescribed mutations. Screening of other exons of APP in 2 families in which we have previously reported mutations at APP717, failed to reveal other sequence abnormalities supporting the hypothesis that the mutations at APP717 cause the disease in these families. These data suggest that mutations in APP are a rare cause of familial early onset AD (3/21 families tested) and that within APP most, possibly all, mutations which cause AD are in exon 17.
在家族性早发性阿尔茨海默病(AD)中发现β-淀粉样前体蛋白(APP)基因突变后,我们开发了一种使用单链构象分析(SSCA)的筛查方案,以筛查APP第17外显子中的已知突变。此外,我们使用该方案对9个早发性AD家族中APP的其他17个外显子以及启动子的一个330碱基对的调控区域进行新突变筛查。在另外10个家族中对编码沉积的β-淀粉样肽的第16和17外显子进行了筛查。我们的筛查程序识别出了APP内所有已报道的突变。虽然我们又发现了一个携带APP717 Val→Ile突变的家族,但未发现任何先前未描述的突变。在我们之前报道过APP717位点突变的2个家族中对APP的其他外显子进行筛查,未发现其他序列异常,这支持了APP717位点突变导致这些家族发病的假说。这些数据表明,APP基因突变是家族性早发性AD的罕见病因(在检测的21个家族中有3个),并且在APP内,大多数(可能是所有)导致AD的突变位于第17外显子。